Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...
Treat or observe? Dr. Joseph Renzulli of Yale School of Medicine shares how he assesses and counsels elderly patients referred for treatment because of elevated PSA levels. (2:44) Fighting Fatigue in ...
Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology ...
A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. Now, with new data indicating the drug could prolong patients’ lives, the company is ...
This has to be looked at as a multifactorial issue, says Joseph Renzulli, MD, of Yale School of Medicine, who shares his perspectives on why that's the case. (3:22) Pelvic Lymph Node Dissection: Is It ...
The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
Hosted on MSN
NCCN Funds Research to Address Side Effects of PARP Inhibitors in Prostate Cancer Treatment
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving the management of side effects ...
Man patient speaking talking doctor receiving chemotherapy treatment iv infusion Platinum chemotherapy is a valid treatment option in patients with BRCA mutations, according to investigators. Poly ADP ...
President Joe Biden speaks onstage during the first day of the Democratic National Convention at the United Center on August 19, 2024 in Chicago, Illinois. Former president Joe Biden has been ...
Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback